Literature DB >> 24107793

Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis.

Ayse L Mindikoglu1, Matthew R Weir.   

Abstract

BACKGROUND: Renal dysfunction is one of the most common complications of cirrhosis with high morbidity and mortality.
SUMMARY: In subjects with cirrhosis, renal dysfunction can present either as a direct consequence of cirrhosis (e.g. hepatorenal syndrome type I and type II) or secondary to etiologies other than cirrhosis (chronic kidney disease due to diabetic nephropathy, prerenal azotemia), or patients with cirrhosis may have renal dysfunction resulting directly from cirrhosis and an underlying chronic kidney disease. KEY MESSAGES: Given the challenges in the differential diagnosis of renal dysfunction and insufficient accuracy of serum creatinine and creatinine-based glomerular filtration rate estimating equations in cirrhosis, there is an urgent need for more accurate biomarkers of renal dysfunction in this population. This review will discuss novel concepts for the diagnosis and classification of renal dysfunction in cirrhosis to overcome at least some of the diagnostic and therapeutic challenges. Additionally, a new classification will be proposed for renal dysfunction in cirrhosis.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24107793      PMCID: PMC4072495          DOI: 10.1159/000355540

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  65 in total

Review 1.  The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.

Authors:  Milan C Richir; Roderick H Bouwman; Tom Teerlink; Michiel P C Siroen; Theo P G M de Vries; Paul A M van Leeuwen
Journal:  JPEN J Parenter Enteral Nutr       Date:  2008 Nov-Dec       Impact factor: 4.016

2.  Plasma cystatin C as a marker of renal function in patients with liver cirrhosis.

Authors:  E Randers; P Ivarsen; E J Erlandsen; E F Hansen; N K Aagaard; F Bendtsen; H Vilstrup
Journal:  Scand J Clin Lab Invest       Date:  2002       Impact factor: 1.713

3.  Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver.

Authors:  A L Gerbes; V Gülberg; M Bilzer; M Vogeser
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

4.  Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites.

Authors:  R Rivolta; A Maggi; M Cazzaniga; D Castagnone; A Panzeri; D Solenghi; E Lorenzano; F Q di Palo; F Salerno
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

5.  Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Anna Köttgen; Elizabeth Selvin; Lesley A Stevens; Andrew S Levey; Frederick Van Lente; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2008-03       Impact factor: 8.860

6.  Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.

Authors:  Lesley A Stevens; Josef Coresh; Christopher H Schmid; Harold I Feldman; Marc Froissart; John Kusek; Jerome Rossert; Frederick Van Lente; Robert D Bruce; Yaping Lucy Zhang; Tom Greene; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2008-03       Impact factor: 8.860

7.  The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis.

Authors:  R J Nijveldt; T Teerlink; P A M van Leeuwen
Journal:  Clin Nutr       Date:  2003-02       Impact factor: 7.324

Review 8.  Assessing renal function in cirrhotic patients: problems and pitfalls.

Authors:  Deb S Sherman; Douglas N Fish; Isaac Teitelbaum
Journal:  Am J Kidney Dis       Date:  2003-02       Impact factor: 8.860

9.  Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality.

Authors:  R J Nijveldt; T Teerlink; B Van Der Hoven; M P C Siroen; D J Kuik; J A Rauwerda; P A M van Leeuwen
Journal:  Clin Nutr       Date:  2003-02       Impact factor: 7.324

10.  The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA).

Authors:  R J Nijveldt; T Teerlink; M P C Siroen; A A van Lambalgen; J A Rauwerda; P A M van Leeuwen
Journal:  Clin Nutr       Date:  2003-02       Impact factor: 7.324

View more
  13 in total

Review 1.  Hepatorenal syndrome: Update on diagnosis and treatment.

Authors:  Olga Baraldi; Chiara Valentini; Gabriele Donati; Giorgia Comai; Vania Cuna; Irene Capelli; Maria Laura Angelini; Maria Ilaria Moretti; Andrea Angeletti; Fabio Piscaglia; Gaetano La Manna
Journal:  World J Nephrol       Date:  2015-11-06

Review 2.  Renal impairment in cirrhosis unrelated to hepatorenal syndrome.

Authors:  Gavin Low; Graeme Jm Alexander; David J Lomas
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04-15

Review 3.  Renal dysfunction in patients with cirrhosis: Where do we stand?

Authors:  Chrysoula Pipili; Evangelos Cholongitas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

Review 4.  Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis.

Authors:  Antonio Facciorusso; Annabianca Amoruso; Viviana Neve; Matteo Antonino; Valentina Del Prete; Michele Barone
Journal:  World J Hepatol       Date:  2014-11-27

Review 5.  New Developments in Hepatorenal Syndrome.

Authors:  Ayse L Mindikoglu; Stephen C Pappas
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-07       Impact factor: 11.382

Review 6.  Renal dysfunction in cirrhosis.

Authors:  Nathalie H Urrunaga; Ayse L Mindikoglu; Don C Rockey
Journal:  Curr Opin Gastroenterol       Date:  2015-05       Impact factor: 3.287

7.  Renal failure in cirrhosis: is it time to change the diagnosis and classification?

Authors:  Suthat Liangpunsakul; Rajiv Agarwal
Journal:  Am J Nephrol       Date:  2013-10-05       Impact factor: 3.754

8.  Role of cystatin C and renal resistive index in assessment of renal function in patients with liver cirrhosis.

Authors:  Dorđe Ćulafić; Miloš Štulić; Radmila Obrenović; Danijela Miletić; Dragana Mijač; Milica Stojković; Marija Jovanović; Milica Ćulafić
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

9.  A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements.

Authors:  Ayse L Mindikoglu; Thomas C Dowling; Jade J Wong-You-Cheong; Robert H Christenson; Laurence S Magder; William R Hutson; Stephen L Seliger; Matthew R Weir
Journal:  Am J Nephrol       Date:  2014-06-17       Impact factor: 3.754

10.  Effectiveness of intravenous infusion of N-acetylcysteine in cirrhotic patients undergoing major abdominal surgeries.

Authors:  Eman Sayed Ibrahim; Ahmed Sharawy
Journal:  Saudi J Anaesth       Date:  2015 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.